An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.

@article{Scagliotti2013AnOM,
  title={An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.},
  author={Giorgio V Scagliotti and E Felip and Benjamin Besse and J. von Pawel and Anders Mellemgaard and Martin Reck and Lionel Bosqu{\'e}e and Christos Chouaid and P Lianes-Barragan and Elaine M Paul and Rodrigo Ruiz-Soto and Entisar Sigal and Lone Harild Ottesen and Thierry Lechevalier},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2013},
  volume={8 12},
  pages={
          1529-37
        }
}
INTRODUCTION This randomized open-label phase II study evaluated the efficacy, safety, and tolerability of pazopanib in combination with pemetrexed compared with the standard cisplatin/pemetrexed doublet in patients with previously untreated, advanced, nonsquamous non-small-cell lung cancer. METHODS Patients were randomized (2:1 ratio) to receive pemetrexed 500 mg/m(2) intravenously once every 3 weeks plus either oral pazopanib 800 mg daily or cisplatin 75 mg/m(2) intravenously once every 3… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Similar Papers

Loading similar papers…